medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2026, Number 1

Next >>

Rev Biomed 2026; 37 (1)

Overview of Type 2 Diabetes in the City of Mérida, Yucatán, Mexico

Valadez-González N, Pinto-Escalante D, Gómez-Pérez E, Alvizo-Perera EJJ, Guerrero-Lara EA, Batún-Cutz JL, Kantún-Chim MD, Pantí-Trejo HG, Cool-Padilla RA, Rangel-Méndez JA, España-Paredes AP

Language: Spanish
References: 30
Page: 1-12
PDF size: 246.62 Kb.


ABSTRACT

Introduction. Among the different types of diabetes, type 2 (T2D) is the most common. Its prevalence varies according to modifiable and nonmodifiable risk factors. Genetic background—whether familial or ethnic (e.g., predominantly Mayan ancestry)—is relevant among the non-modifiable risks. The implementation of public health strategies benefits from an understanding of the characteristics of the target population. Therefore, the aim of this study was to estimate the prevalence of T2D and its associated risk factors in adults from Mérida, Yucatán, Mexico.
Methods. A cross-sectional, survey-based study was conducted in 1,699 adults (20–69 years old) from Mérida, Yucatán, Mexico. Additionally, a subgroup underwent glycated hemoglobin (HbA1c) testing and was classified as having prediabetes, T2D (pre-existing or newly diagnosed), or normoglycemia.
Results. The survey estimated a T2D prevalence of 13.1%. In the subgroup that provided blood samples, 16.4% had T2D (2.6% were newly diagnosed cases), and 8.7% had prediabetes. T2D and prediabetes groups shared risk factors such as older age and family history of diabetes. In prediabetes, female sex and obesity were additional risk factors; hypertension was an additional factor for T2D.
Conclusions. Identifying the prevalence of T2D and its associated risk factors in adults from Mérida, Yucatán, highlights an opportunity for the Mexican health system to strengthen prevention and early detection strategies in this and other urbanized regions with similar health contexts.


REFERENCES

  1. World Health Organization (WHO). Diabetes [Internet]. 2023 [cited 2025 Jun 11]. Disponible en: https://www.who.int/health-topics/diabetes#tab=tab_1

  2. Institute for Health Metrics and Evaluation (IHME).GBD 2021 Cause and Risk Summary [Internet]. 2025[cited 2025 Aug 18]. Disponible en: https://vizhub.healthdata.org/gbd-results/

  3. American Diabetes Association. Standards of MedicalCare in Diabetes-2022 Abridged for Primary CareProviders. Clinical diabetes. 2022 Jan 1;40(1):10–38.

  4. Longo M, Zatterale F, Naderi J, Parrillo L, FormisanoP, Raciti GA, et al. Adipose Tissue Dysfunctionas Determinant of Obesity-Associated MetabolicComplications. Int J Mol Sci. 2019 May 1;20(9):2358.

  5. Centers for Disease Control and Prevention (CDC).Diabetes Risk Factors [Internet]. 2023 [cited 2023 Mar1]. Disponible en: https://www.cdc.gov/diabetes/basics/risk-factors.html

  6. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R,Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M,et al. Prevalencia de prediabetes y diabetes en México:Ensanut 2022. Salud Publica Mex. 2023;65(1):s163–8.

  7. Instituto Nacional de Salud Pública. Encuesta Nacionalde Salud y Nutrición (ENSANUT) 2021 [Internet]. 2021[cited 2023 Mar 9]. Disponible en: https://ensanut.insp.mx/encuestas/ensanutcontinua2021/informes.php

  8. Instituto Nacional de Salud Pública. Encuesta Nacionalde Salud y Nutrición (ENSANUT) 2018 [Internet]. 2018[cited 2023 Mar 2]. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/informes.php

  9. Barquera S, Hernández-Alcaraz C, Jáuregui A, MedinaC, Mendoza-Herrera K, Pedroza-Tobias A, et al. DiabetesAwareness, Treatment, and Control among Mexico CityResidents. Diabetology. 2021 Feb 18;2(1):16–30.

  10. Rubi-Castellanos R, Martínez-Cortés G, Muñoz-ValleJ, González-Martín A, Cerda-Flores R, Anaya-PalafoxM, et al. Pre-Hispanic Mesoamerican demographyapproximates the present-day ancestry of Mestizosthroughout the territory of Mexico. Am J Phys Anthropol.2009;139(3):284–94.

  11. Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J,Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A,et al. Analysis of genomic diversity in Mexican Mestizopopulations to develop genomic medicine in Mexico.Proc Natl Acad Sci U S A. 2009;106(21):8611–6.

  12. Lara-Riegos JC, Ortiz-López MG, Peña-Espinoza BI,Montúfar-Robles I, Peña-Rico MA, Sánchez-Pozos K,et al. Diabetes susceptibility in Mayas: Evidence forthe involvement of polymorphisms in HHEX, HNF4α,KCNJ11, PPARγ, CDKN2A/2B, SLC30A8, CDC123/CAMK1D, TCF7L2, ABCA1 and SLC16A11 genes.Gene. 2015 Jul 1;565(1):68–75.

  13. Secretaría de Salud. Encuesta Nacional de Salud2018. Informe de resultados. [Internet]. 2018 [cited2022 Aug 25]. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf

  14. Cochran WG. Sampling Techniques. 3rd ed. New York,USA: John Wiley and Sons Inc.; 1997. 1–422 p.

  15. von Elm E, Altman DG, Egger M, Pocock SJ, GøtzschePC, Vandenbroucke JP. The Strengthening the Reportingof Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies.J Clin Epidemiol. 2008 Apr;61(4):344–9.

  16. World Health Organization (WHO). Waistcircumference and waist-hip ratio: report of a WHOexpert consultation [Internet]. 2011 [cited 2024 May30]. Disponible en: https://www.who.int/publications/i/item/9789241501491

  17. World Health Organization (WHO). Obesity andoverweight [Internet]. 2023 [cited 2023 Dec 3].Disponible en: https://www.who.int/news-room/factsheets/detail/obesity-and-overweight

  18. Secretaría de Salud. NORMA Oficial Mexicana NOM-043-SSA2-2012, Servicios básicos de salud. Promocióny educación para la salud en materia alimentaria.Criterios para brindar orientación. 2013.

  19. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR,Brown FM, Bruemmer D, et al. Glycemic goals andhypoglycemia: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S111–25.

  20. International Diabetes Federation. IDF Diabetes Atlas.10th ed. Brussels, Belgium: International DiabetesFederation; 2021.

  21. Seclen SN, Rosas ME, Arias AJ, Huayta E, MedinaCA. Prevalence of diabetes and impaired fastingglucose in Peru: report from PERUDIAB, a nationalurban population-based longitudinal study. BMJ OpenDiabetes Res Care. 2015 Oct 1;3(1):e000110.

  22. Lima Y de MM, Martins FA, Ramalho AA. Epidemiologyof Diabetes Mellitus in Adults and Seniors in Rio Branco,Acre, Western Brazilian Amazon. Diabetology 2024, Vol5, Pages 151-161. 2024 Apr 10;5(2):151–61.

  23. Jonas DE, Crotty K, Yun JDY, Middleton JC, FeltnerC, Taylor-Phillips S, et al. Screening for Prediabetesand Type 2 Diabetes: Updated Evidence Report andSystematic Review for the US Preventive Services TaskForce. JAMA. 2021 Aug 24;326(8):744–60.

  24. Cətoi AF, Pârvu A, Mureşan A, Busetto L. MetabolicMechanisms in Obesity and Type 2 Diabetes: Insightsfrom Bariatric/Metabolic Surgery. Obes Facts. 2015 Dec1;8(6):350–63.

  25. Flor LS, Campos MR. The prevalence of diabetesmellitus and its associated factors in the Brazilian adultpopulation: evidence from a population-based survey.Rev Bras Epidemiol. 2017;20(1):16–29.

  26. Shrestha N, Karki K, Poudyal A, Aryal KK, MahatoNK, Gautam N, et al. Prevalence of diabetes mellitusand associated risk factors in Nepal: findings froma nationwide population-based survey. BMJ Open.2022;12(2):e060750.

  27. Dávila-Cervantes CA, Agudelo-Botero M. Sexdisparities in the epidemic of type 2 diabetes in Mexico:national and state level results based on the GlobalBurden of Disease Study, 1990–2017. Diabetes MetabSyndr Obes. 2019;12:1023.

  28. Seiglie JA, Franco RR, Wirtz VJ, Meigs JB, MendozaMA, Miranda JJ, et al. Regional and state-level patternsof type 2 diabetes prevalence in Mexico over the lastthree decades. Diabetes Res Clin Pract. 2021 Jul 1;177.

  29. Pinto-Escalante D, Ruiz-García L, García-Escalante MG,Valadez-González N, Rubi-Castellanos R, Vera-GamboaL, et al. Análisis genealógico de diabetes tipo 2 enfamilias extensas multigeneracionales de una comunidadyucateca. Revista Biomédica. 2024;35(1):1–9.

  30. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension,and Cardiovascular Disease: Clinical Insights andVascular Mechanisms. Can J Cardiol. 2018 May1;34(5):575–84.




2020     |     www.medigraphic.com